New drug candidates fail during development for many reasons, centred around:
Undesirable absorption and/or metabolism of the compound in man
Poor solubility over the physiological pH range
Poor stability of the compound in the gastrointestinal environment
With the constant demands on pharmaceutical scientists to reduce time and cost for development of new drugs, selecting the ‘winners’ and identifying the ‘losers’ in a selection of compounds can increase the chances of success in clinic and help achieve the drug development goals.
Juniper Pharma Services and XenoGesis work together successfully to provide an integrated bio-pharmaceutics service offering. The unique combined approach helps to remove the gap between ‘chemical’ and ‘biological’ to provide the most effective drug delivery solutions.
This approach can help pharmaceutical and biotechnology companies:
- Predict how a drug will behave in vivo
- Pave the way to human-optimised medicines
◦ Maximize exposure for toxicological studies
◦ Maximize or modify drug delivery for clinical trials
- Optimise drug performance by tailored formulation strategy
The webinar will demonstrate and explain how our joint, consultative approach to drug development, along with our unique Enabling Technologies Rapid Screen can help you to take your compound through to clinic in a seamless, rapid and cost-effective way.
Robert Harris, PhD, CChem, FRSC, Chief Technical Officer, Juniper Pharma Services
Rob has over 30 years experience in the Pharmaceutical industry. He started his career in production support roles with Warner Lambert and GSK before spending time in academia as a Research Fellow at the University of Manchester, where his research work involved the development of novel drug delivery systems. For the last 15 years Rob has worked in the contract Pharmaceutical development sector, holding senior technical roles with Quay Pharma, Capsugel and Penn Pharma. He is currently Chief Technical Officer with juniper Pharma Services. He maintains a keen interest in drug delivery and its challenges, with a particular focus on oral delivery of poorly soluble compounds.
Richard Weaver PhD, FRSC, Founder and Managing Director, XenoGesis
Having joined Astra Charnwood in 1997 within Discovery DMPK, Richard progressed to Group and Project Leader at AstraZeneca. During that time Richard gained and developed an in-depth knowledge of all aspects of in vitro and in vivo Drug Metabolism and Pharmacokinetics from Hit Identification to Candidate Drug nomination and beyond.
In 2011, Richard spotted an opportunity in the market and set up XenoGesis. His clear direction, vision and entrepreneurial approach to running a business has seen XenoGesis expand from 3 to 18 employees in just over three years, as well as now supporting over 100 companies and Universities around the world. His ambition is to build on this growth in the coming years whilst focusing on the XenoGesis reputation of providing a consultative approach to preclinical DMPK, TK and Bioanalysis projects to help clients achieve their drug discovery goals.
Richard gained a first class honours degree in chemistry with awards for the best performance in every year, followed by a medicinal chemistry PhD with a Wellcome Trust scholarship at the University of Leicester and two subsequent postdoctoral positions at the Welsh School of Pharmacy. He has authored and co-authored twenty one publications to date and in 2014, Richard was invited to become a Fellow of the Royal Society of Chemistry.
Who Should Attend?
- Senior biotech executives
- CMC consultants
- Formulation scientists
- Pre-clinical scientists
- Pharmaceutical development directors and department heads
- Senior professionals involved in the early development of new drugs (discovery – pre-clinical – formulation development)
Juniper Pharma Services
Juniper Pharma Services and XenoGesis provide a consultative approach to ensure the most effective outcomes, helping their clients achieve translation from drug discovery into full development.
Combined expertise in one team gives clients a seamless and comprehensive service all the way through to formulation development and to the clinic.
Together, Juniper Pharma Services and XenoGesis provide a better understanding of a compound’s bioavailability, and a smarter and quicker approach for drug product development. This in turn can reduce cost and add value to development projects.